Christian Itin
Founder & CSO
Dr Martin Pule
% Shareholding
Number of employees
NASDAQ (June 2018)
Clinical trials

*Unless stated all financials at 30 June 2021

Autolus website

Autolus is a clinical-stage biopharmaceutical company focusing on the development of precisely targeted, controlled and highly active T effector cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.

Autolus is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Chimeric Antigen Receptor (CAR) T cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential for cure in some patients.

A leader in T-cell programming and manufacturing technology, Autolus works in partnership with physicians and other healthcare providers to extract immune cells from patients, equip them with a receptor that targets the cancer cell and infuse them back into the patient in order to develop therapies which they believe will offer cancer patients substantial benefits over the existing standard of care.


Investment opportunity

  • No CAR-T therapy approved for adult Acute Lymphoblastic Leukaemia (aALL) patients
  • AUTO1 has a differentiated safety profile and improved persistence to address limitations of current T cell therapies
  • AUTO4 targeting T-cell lymphoma, a setting where there are currently no approved T cell therapies and substantial unmet clinical needs

Unmet medical need:

  • In lead programme of AUTO1, only 30-40% of patients with aALL achieve long term remission with combination chemotherapy, the current standard of care*

Market Opportunity*

  • 8,400 patients p.a. in lead programme of aALL (estimated new patients globally diagnosed per annum)
  • Estimated 3,000 relapsed / refractory ALL patients in EU / US

Key risks

  • Highly competitive environment
  • Differentiated product requirement 
  • Complex manufacturing and supply chain

*Autolus corporate presentation - May 2021

The Autolus pipeline

Research Pre-clinical Clinical
  • AUTO1 / Adult ALL*

  • AUTO 1/22 -pALL

  • AUTO4 - T cell Lymphoma

*Includes ALLCAR Phase 1 and Felix Phase 1b/2 studies

Syncona team

Martin Murphy

Martin Murphy

Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Resolution Therapeutics. He is Chairman of Quell and Anaveon and i…
View Martin's biography
Board member
Freddie Dear

Freddie Dear

Freddie is a Partner of Syncona Investment Management Ltd. He has been closely involved with Quell Therapeutics where he spent a year as Director of Operations and serves as an Observer on the Board. Previously, he was a member of the Investment Team at the Wellcome Trust, which is responsible for the management of its £23 billion global investment portfolio. Freddie holds a degree in Biochemistry…
View Freddie's biography

Autolus leaders and founders

Dr Christian Itin

Dr Christian Itin

Chief Executive Officer
Dr Martin Pule

Dr Martin Pule

Senior Vice President, Founder and Chief Scientific Officer

Autolus publications & presentations

Show presentations from

Autolus Corporate Presentation - August 2021

Download PDF (1.06Mb)

Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress

Download PDF (0.47Mb)

Autolus Corporate Presentation - July 2021

Download PDF (1.08Mb)

Autolus EHA June 2021

Download PDF (0.68Mb)

Other cell therapy portfolio companies